About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
For information about YCANTHâ„¢ or to request a representative, visit YCANTHPro.com
Document Details
Form: 3
Filing Date: June 14, 2018
Document Date: June 14, 2018
Form Description: Initial filing by director officer or owner of more than ten percent.
Filing Group:
3-4-5
Company: Verrica Pharmaceuticals
Filer: PRYGOCKI MARK A SR
Filing Formats
View HTML
Download PDF
Download DOC
Download XLS